ARCUS BIOSCIENCES INC (RCUS) Stock Analyst Ratings
USA - New York Stock Exchange - NYSE:RCUS - US03969F1093 - Common Stock
22.13 USD
-0.93 (-4.03%)
22.1 USD
-0.03 (-0.14%)
ChartMill assigns a Buy % Consensus number of 82% to RCUS. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 33.66. This target is 52.1% above the current price.
- RCUS was analyzed by 18 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about RCUS.
- In the previous month the buy percentage consensus was at a similar level.
- RCUS was analyzed by 18 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-01-13 | Goldman Sachs | Upgrade | Neutral -> Buy |
| 2026-01-08 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2025-12-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-28 | B of A Securities | Maintains | Neutral -> Neutral |
| 2025-10-30 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-10-29 | Citigroup | Maintains | Buy -> Buy |
| 2025-10-29 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-20 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-10-13 | Citigroup | Maintains | Buy -> Buy |
| 2025-10-07 | Truist Securities | Reiterate | Buy -> Buy |
| 2025-08-07 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-05-09 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-05-08 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-05-07 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-04-23 | Barclays | Maintains | Overweight -> Overweight |
| 2025-02-26 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2025-02-19 | B of A Securities | Maintains | Neutral -> Neutral |
| 2025-02-18 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-02-18 | HC Wainwright & Co. | Maintains | Neutral -> Neutral |
| 2024-11-06 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-10-25 | Barclays | Maintains | Overweight -> Overweight |
| 2024-10-24 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-10-21 | HC Wainwright & Co. | Initiate | Neutral |
| 2024-10-08 | Wells Fargo | Initiate | Overweight |
| 2024-10-07 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-10-03 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-10-03 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-08-09 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-08-09 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-07-08 | Barclays | Maintains | Overweight -> Overweight |
ARCUS BIOSCIENCES INC / RCUS FAQ
What is the average price target for ARCUS BIOSCIENCES INC (RCUS) stock?
18 analysts have analysed RCUS and the average price target is 33.66 USD. This implies a price increase of 52.1% is expected in the next year compared to the current price of 22.13.
What is the consensus rating for RCUS stock?
The consensus rating for ARCUS BIOSCIENCES INC (RCUS) is 82.2222 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for RCUS stock?
The number of analysts covering ARCUS BIOSCIENCES INC (RCUS) is 18.